First Step With Singulair® Therapy (0476-323) (FIRST)
Primary Purpose
Asthma
Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
MK0476 (singulair), montelukast sodium / Duration of Treatment: 6 Weeks
Comparator: Fluticasone / Duration of Treatment: 6 Weeks
Sponsored by

About this trial
This is an interventional treatment trial for Asthma
Eligibility Criteria
Inclusion Criteria:
- First time diagnosis of mild asthma symptoms which requires an antiinflammatory controller medication
- Patients not controlled with short acting beta2 agonist (sab) therapy (requiring more than one treatment per week but less than 7 per week)
- Patients dissatisfied with low dose ics therapy, or patients reluctant to take ics therapy, or patients insufficiently controlled due to non-compliance with low dose ics therapy through out the preceding 6 weeks
- Patient's forced expiratory volume in one second (fev1) is < 80% of predicted value
Exclusion Criteria:
- Patient on combination therapy
- Patient on long acting beta2 agonists
- Patient on using moderate to high doses of ICS. (ICS >250 µ g/day flovent® or equivalent per day)
Sites / Locations
Outcomes
Primary Outcome Measures
Canadian asthma guidelines criteria
Secondary Outcome Measures
Asthma control questionnaire
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00545324
Brief Title
First Step With Singulair® Therapy (0476-323)
Acronym
FIRST
Official Title
A 12 Week Multicenter, Open-Label, Randomized, Observational Study Comparing Singulair® 10 Mg As Controller Monotherapy In Adults With Mild Asthma "To Low Dose" Inhaled Corticosteroid Treatment
Study Type
Interventional
2. Study Status
Record Verification Date
January 2022
Overall Recruitment Status
Completed
Study Start Date
September 2002 (undefined)
Primary Completion Date
December 2003 (Actual)
Study Completion Date
December 2003 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Organon and Co
4. Oversight
5. Study Description
Brief Summary
In adult patients with mild persistent asthma, singulair® 10 mg will be at least as effective as low dose Inhaled Corticosteroids (ICS) in improving asthma symptom control or satisfaction over a 6 week comparison period.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
399 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
MK0476 (singulair), montelukast sodium / Duration of Treatment: 6 Weeks
Intervention Type
Drug
Intervention Name(s)
Comparator: Fluticasone / Duration of Treatment: 6 Weeks
Primary Outcome Measure Information:
Title
Canadian asthma guidelines criteria
Secondary Outcome Measure Information:
Title
Asthma control questionnaire
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
First time diagnosis of mild asthma symptoms which requires an antiinflammatory controller medication
Patients not controlled with short acting beta2 agonist (sab) therapy (requiring more than one treatment per week but less than 7 per week)
Patients dissatisfied with low dose ics therapy, or patients reluctant to take ics therapy, or patients insufficiently controlled due to non-compliance with low dose ics therapy through out the preceding 6 weeks
Patient's forced expiratory volume in one second (fev1) is < 80% of predicted value
Exclusion Criteria:
Patient on combination therapy
Patient on long acting beta2 agonists
Patient on using moderate to high doses of ICS. (ICS >250 µ g/day flovent® or equivalent per day)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Monitor
Organizational Affiliation
Merck Sharp & Dohme LLC
Official's Role
Study Director
12. IPD Sharing Statement
Available IPD and Supporting Information:
Available IPD/Information Type
CSR Synopsis
Available IPD/Information URL
http://www.merck.com/clinical-trials/policies-perspectives.html
Learn more about this trial
First Step With Singulair® Therapy (0476-323)
We'll reach out to this number within 24 hrs